Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
Hope DCD, Tan TM-M, 2023, Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy., Peptides, Vol:162
et al., 2023, Letter to the Editor of Clinical Endocrinology: Assessment of adrenal function in patients who survive COVID‐19, Clinical Endocrinology, Vol:98, ISSN:0300-0664, Pages:270-272
Tan TM-M, 2022, Co-agonist therapeutics come of age for obesity, Nature Reviews Endocrinology, Vol:19, ISSN:1759-5029, Pages:66-67
et al., 2022, The postprandial secretion of peptide YY1-36 and (3-36) in obesity is differentially increased after gastric bypass versus sleeve gastrectomy, Clinical Endocrinology, ISSN:0300-0664
et al., 2022, Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss, Cell Reports Medicine, Vol:3, ISSN:2666-3791